AR118413A1 - Un compuesto que contiene oxadiazol y una composición farmacéutica que contiene el mismo - Google Patents
Un compuesto que contiene oxadiazol y una composición farmacéutica que contiene el mismoInfo
- Publication number
- AR118413A1 AR118413A1 ARP190102667A ARP190102667A AR118413A1 AR 118413 A1 AR118413 A1 AR 118413A1 AR P190102667 A ARP190102667 A AR P190102667A AR P190102667 A ARP190102667 A AR P190102667A AR 118413 A1 AR118413 A1 AR 118413A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkoxyalkyl
- haloalkyl
- hydroxyalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen los compuestos de oxadiazol y las sales farmacéuticamente aceptables de ellos. Los compuestos y las sales farmacéuticamente aceptables de ellos son específicamente adecuados para el tratamiento de enfermedades neurológicas tales como la epilepsia. Reivindicación 1: Un compuesto representado mediante la fórmula química (1), o un estereoisómero, un isómero óptico o su sal farmacéuticamente aceptable, en el cual, R¹ se selecciona entre el grupo que consiste en las fórmulas del grupo de fórmulas (2); R² es hidrógeno, halo, hidroxi, alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, carbamoiloxi, alcoxi, alquiltio, haloalcoxi, o hidroxialcoxi; R³ es hidrógeno, alquilo, cicloalquilo, haloalquilo, hidroxialquilo, alcoxialquilo, carbamoílo, alquilcarbamoílo, dialquilcarbamoílo, carbonilo, o alquilcarbonilo; R⁴ es hidrógeno, halo, hidroxi, alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, carbamoílo, alquilcarbamoílo, o dialquilcarbamoílo; R⁵ es hidrógeno, halo, hidroxi, alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, carbamoílo, alquilcarbamoílo, o dialquilcarbamoílo; R⁶, R⁷, R⁸ y R⁹ son, cada uno en forma independiente, hidrógeno, halo, alquilo, haloalquilo, hidroxialquilo, alcoxialquilo, carbamoiloxialquilo, alquil-C(O)O-alquilo, alcoxi, alquiltio, haloalcoxi, hidroxialcoxi, alcoxi-alcoxi, carbamoiloxialcoxi, alquil-C(O)O-alcoxi, amino, dialquilamino, carbonilamino, alquilcarbonilamino, haloalquil-carbonilamino, o heterocicloalquilo que tiene entre 1 y 3 átomos de nitrógeno (N); X, Y y Z son, cada uno en forma independiente, seleccionados entre el grupo que consiste en nitrógeno (N) y oxígeno (O), en donde al menos uno entre X, Y o Z es oxígeno (O); m es un número entero comprendido entre 0 y 3; n, o, y p son, cada uno en forma independiente, un número entero comprendido entre 0 y 5 y q es un número entero comprendido entre 0 y 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180113956 | 2018-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118413A1 true AR118413A1 (es) | 2021-10-06 |
Family
ID=69887571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102667A AR118413A1 (es) | 2018-09-21 | 2019-09-20 | Un compuesto que contiene oxadiazol y una composición farmacéutica que contiene el mismo |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11053208B2 (es) |
| EP (1) | EP3854788A4 (es) |
| JP (1) | JP7430175B2 (es) |
| KR (1) | KR20210047889A (es) |
| CN (1) | CN113272285B (es) |
| AR (1) | AR118413A1 (es) |
| AU (1) | AU2019341357B2 (es) |
| BR (1) | BR112021005269A2 (es) |
| CA (1) | CA3112700A1 (es) |
| CL (1) | CL2021000618A1 (es) |
| IL (1) | IL281553A (es) |
| MX (1) | MX2021003204A (es) |
| TW (1) | TWI826531B (es) |
| WO (1) | WO2020060299A1 (es) |
| ZA (1) | ZA202101520B (es) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US21121A (en) | 1858-08-10 | Appabattjs for purifying gas | ||
| DK153787C (da) | 1979-06-01 | 1989-01-16 | Wellcome Found | Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved |
| GB8412357D0 (en) | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
| KR0162036B1 (ko) | 1996-05-31 | 1998-12-01 | 추호석 | 스택커 크래인의 모터 제어장치 및 방법 |
| AU740813B2 (en) * | 1998-07-08 | 2001-11-15 | Monash University | Pharmaceutical agents |
| UA78211C2 (en) | 2001-07-09 | 2007-03-15 | Ortho Mcneil Pharm Inc | Salts of fructopyranose derivatives as anticonvulsant |
| AU2005271669A1 (en) * | 2004-08-03 | 2006-02-16 | Merck & Co., Inc. | 1,3-disubstituted heteroaryl NMDA/NR2B antagonists |
| US7598279B2 (en) * | 2005-04-22 | 2009-10-06 | Sk Holdings Co., Ltd. | Neurotherapeutic azole compounds |
| US9102622B2 (en) * | 2006-07-28 | 2015-08-11 | University Of Connecticut | Fatty acid amide hydrolase inhibitors |
| PT2239253E (pt) | 2008-02-06 | 2013-09-17 | Daiichi Sankyo Co Ltd | Novo derivado de fenilpirrole |
| AU2010339271B2 (en) | 2009-12-28 | 2015-09-03 | General Incorporated Association Pharma Valley Project Supporting Organization | 1,3,4-oxadiazole-2-carboxamide compound |
| PT2544679T (pt) * | 2010-03-12 | 2019-07-11 | Omeros Corp | Inibidores de pde-10 e composições e métodos relacionados |
| WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
-
2019
- 2019-09-19 TW TW108133837A patent/TWI826531B/zh active
- 2019-09-20 AU AU2019341357A patent/AU2019341357B2/en active Active
- 2019-09-20 BR BR112021005269-0A patent/BR112021005269A2/pt unknown
- 2019-09-20 KR KR1020217007242A patent/KR20210047889A/ko not_active Application Discontinuation
- 2019-09-20 JP JP2021516367A patent/JP7430175B2/ja active Active
- 2019-09-20 MX MX2021003204A patent/MX2021003204A/es unknown
- 2019-09-20 EP EP19863530.2A patent/EP3854788A4/en active Pending
- 2019-09-20 CN CN201980076515.0A patent/CN113272285B/zh active Active
- 2019-09-20 WO PCT/KR2019/012257 patent/WO2020060299A1/ko active Application Filing
- 2019-09-20 CA CA3112700A patent/CA3112700A1/en active Pending
- 2019-09-20 AR ARP190102667A patent/AR118413A1/es unknown
- 2019-09-20 US US16/613,659 patent/US11053208B2/en active Active
-
2021
- 2021-03-05 ZA ZA2021/01520A patent/ZA202101520B/en unknown
- 2021-03-12 CL CL2021000618A patent/CL2021000618A1/es unknown
- 2021-03-16 IL IL281553A patent/IL281553A/en unknown
- 2021-05-24 US US17/327,928 patent/US11603358B2/en active Active
-
2023
- 2023-01-18 US US18/155,924 patent/US20230150955A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3854788A1 (en) | 2021-07-28 |
| US11603358B2 (en) | 2023-03-14 |
| CA3112700A1 (en) | 2020-03-26 |
| WO2020060299A1 (ko) | 2020-03-26 |
| US20210115001A1 (en) | 2021-04-22 |
| KR20210047889A (ko) | 2021-04-30 |
| CN113272285A (zh) | 2021-08-17 |
| CL2021000618A1 (es) | 2021-08-06 |
| JP2022503775A (ja) | 2022-01-12 |
| AU2019341357A1 (en) | 2021-04-08 |
| JP7430175B2 (ja) | 2024-02-09 |
| AU2019341357B2 (en) | 2023-03-02 |
| ZA202101520B (en) | 2022-08-31 |
| TWI826531B (zh) | 2023-12-21 |
| US20230150955A1 (en) | 2023-05-18 |
| US20220024886A1 (en) | 2022-01-27 |
| US11053208B2 (en) | 2021-07-06 |
| IL281553A (en) | 2021-05-31 |
| CN113272285B (zh) | 2024-06-07 |
| TW202023547A (zh) | 2020-07-01 |
| BR112021005269A2 (pt) | 2021-06-15 |
| MX2021003204A (es) | 2021-05-27 |
| EP3854788A4 (en) | 2022-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR109595A1 (es) | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| AR100160A1 (es) | 1H-PIRROLO[2,3-c]PIRIDIN-7(6H)-ONAS Y PIRAZOLO[3,4-c]PIRIDIN-7(6H)-ONAS COMO INHIBIDORES DE PROTEÍNAS BET | |
| AR087591A1 (es) | Derivados de ciclohexil azetidina como inhibidores de jak | |
| AR085318A1 (es) | Derivados de triazol que tienen actividad insecticida | |
| AR084308A1 (es) | Compuestos insecticidas derivados de triazol | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR094452A1 (es) | COMPUESTOS HETEROCÍCLICOS SUSTITUIDOS CON AMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O INFa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100463A1 (es) | Composiciones pesticidas y métodos relacionados | |
| AR106070A1 (es) | Benzamidas sustituidas con isoxazolina como insecticidas | |
| AR110769A1 (es) | Compuestos de 1h-indazol, composición farmacéutica que lo comprende y su uso para fabricar un medicamento | |
| AR090376A1 (es) | Compuestos herbicidas | |
| AR115936A1 (es) | Compuestos útiles en terapia del vih | |
| AR118413A1 (es) | Un compuesto que contiene oxadiazol y una composición farmacéutica que contiene el mismo | |
| AR102019A1 (es) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profármacos para el tratamiento de trastornos psiquiátricos | |
| AR088639A1 (es) | Composicion farmaceutica oftalmica, compuestos antimicrobianos a base de carbolina | |
| AR125448A1 (es) | Moduladores de trex1 | |
| AR121554A1 (es) | Azálidos de urea inmunoduladores | |
| AR103826A2 (es) | Compuestos para su uso terapéutico en seres humanos y/o animales superiores, composición plaguicida, usos y método de control |